2021 Opportunities For Healthtech Investment: A Legal Firm’s View
For life sciences investors, the past year has been the busiest period in recent memory, say Goodwin partners Sophie McGrath and David Mardle. But what are the industry's drivers and key investor trends in 2021?
You may also be interested in...
As the value of medtech deals increases, investors are increasingly looking for earlier opportunities. COVID-19 has added both impetus and new opportunity, with innovators and investors vying to build a position in digital health technologies, such as remote monitoring and digital therapeutics.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.